OTCMKTS:ALPMY Astellas Pharma Q4 2025 Earnings Report $15.06 -0.29 (-1.89%) As of 03:59 PM Eastern ProfileEarnings HistoryForecast Astellas Pharma EPS ResultsActual EPS$0.27Consensus EPS $0.15Beat/MissBeat by +$0.12One Year Ago EPSN/AAstellas Pharma Revenue ResultsActual Revenue$3.22 billionExpected Revenue$3.02 billionBeat/MissBeat by +$205.66 millionYoY Revenue GrowthN/AAstellas Pharma Announcement DetailsQuarterQ4 2025Date4/25/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsAstellas Pharma's next earnings date is estimated for Thursday, October 29, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Astellas Pharma Earnings HeadlinesMizuho Securities Sticks to Their Hold Rating for Astellas Pharma (ALPMF)September 15, 2026 | theglobeandmail.comAstellas Pharma (ALPMF) Receives a Hold from Morgan StanleyAugust 20, 2026 | theglobeandmail.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 23 at 1:00 AM | Weiss Ratings (Ad)Astellas Halts Early KRAS G12D Cancer Trial: What It Means for ALPMF InvestorsJuly 16, 2026 | tipranks.comSangamo bankruptcy puts gene therapy platforms in play, Eli Lilly and Astellas circleJune 23, 2026 | msn.comAstellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 4, 2026 | seekingalpha.comSee More Astellas Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email. Email Address About Astellas PharmaAstellas Pharma (OTCMKTS:ALPMY) is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions. The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes. Astellas also develops and commercializes products through collaborations with other pharmaceutical and biotechnology companies, including PADCEV for bladder cancer. Astellas was established in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical and is headquartered in Tokyo, Japan. It operates research, development and commercial activities across Japan, the United States, Europe and other international markets. Naoki Okamura serves as the company’s president and chief executive officer.View Astellas Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
